You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康基醫療(09997.HK):上半年歸母淨利潤達到2.66億元

格隆匯8月28日丨康基醫療(09997.HK)發佈公告,截至2025年6月30日止六個月,報告期內,公司實現人民幣4.97億元的收入,相較2024年同期增長8.3%,母公司擁有人應佔純利達到人民幣2.66億元。報告期內,集團於中國新增5項產品註冊(不計及續新)。截至2025年6月30日,集團共擁有113項中國國家藥品監督管理局(NMPA)國內註冊,包括17項第三類醫療器械、61項第二類醫療器械和35項第一類醫療器械。於報告期內,集團亦於中國取得21項新專利授權,而唯精醫療則單獨成功獲得23項新專利授權。

集團高度重視產品研發,並計劃持續增加研發開支。集團目前的產品組合包含豐富的微創手術設備、器械和耗材,涵蓋整個手術流程,從創建通路和建立腹腔氣腹,到術中切割、解剖、凝固、閉合、視覺化系統和傷口閉合,可提供完整的一站式微創手術解決方案。2025年上半年,集團的多項產品獲得中國國家藥品監督管理局的批準,包括集團的4K3D螢光內窺鏡攝像系統、4K3D螢光腹腔鏡、硬性宮腔鏡和一次性膀胱鏡。同時,集團的集成式超聲與高頻手術刀、微波消融儀以及一次性微波消融電極均已進入註冊審查階段,預計將於2025年下半年獲得批準。在集團的手術縫合線產品組合中,去年推出的可吸收免打結縫合線滿足重要臨牀需求。這款創新產品具有優越的生物相容性,適用於多種臨牀應用場景,並具備多種規格可供選擇,可滿足不同的手術需求。此外,集團新推出的連發結紮夾和連發鈦夾則透過全面的結紮與閉合解決方案提高手術效率,目前集團正針對該等產品進行臨牀市場推廣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account